Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
650 stopped studies mapped to Myeloid Leukemia and descendants · 88% state a reason
Over the 650 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04748848 | A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With… | Phase 1 | terminated | Feb 10, 2021 | Celgene | Business objectives have changed. | Sponsor / business decision |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | Phase 1 | withdrawn | Aug 24, 2022 | Shanghai Pudong Hospital | The study is not initiated and we want it to be withdrawn. | Other (stated, no rule matched) |
| NCT04530695 | Diagnosis and Treatment of Periodontal Disease in Patients With AML | N/A | withdrawn | Aug 28, 2020 | Masonic Cancer Center, University of Minnesota | PI left institution and research was cancelled due to his departure | Investigator |
| NCT04326764 | Panobinostat Maintenance After HSCT fo High-risk AML and MDS | Phase 3 | terminated | Mar 30, 2020 | Goethe University | Change of marketing authorisation holder | Other (stated, no rule matched) |
| NCT00589316 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body… | Phase 1 | terminated | Jan 9, 2008 | Fred Hutchinson Cancer Center | Terminated due to loss of funding | Funding |
| NCT02543749 | DC Vaccination in CML | Phase 1 / Phase 2 | terminated | Sep 7, 2015 | Charite University, Berlin, Germany | not stated | Not stated |
| NCT05223699 | Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and… | Phase 1 | terminated | Feb 4, 2022 | Magenta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT02323113 | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute… | Phase 1 / Phase 2 | terminated | Dec 23, 2014 | Calithera Biosciences, Inc | Business Decision; No Safety or Efficacy Concerns. | Safety / toxicity |
| NCT04095858 | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease…(CATHY) | Phase 3 | terminated | Sep 19, 2019 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business Reasons | Sponsor / business decision |
| NCT00573378 | Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia | Phase 2 | terminated | Dec 14, 2007 | University of Michigan Rogel Cancer Center | not stated | Not stated |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT00887926 | Study of IMC-EB10 in Participant With Leukemia | Phase 1 | terminated | Apr 24, 2009 | Eli Lilly and Company | Lack of efficacy | Efficacy / futility |
| NCT00119366 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and… | Phase 2 | terminated | Jul 13, 2005 | Fred Hutchinson Cancer Center | Funding ended before target accrual was reached; participants are no longer being examined or… | Enrollment / accrual |
| NCT04402723 | Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML | Phase 1 | terminated | May 27, 2020 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Corporate policy adjustments | Other (stated, no rule matched) |
| NCT04595851 | Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer… | N/A | terminated | Oct 22, 2020 | University of Michigan Rogel Cancer Center | accrual difficulties | Enrollment / accrual |
| NCT03214666 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | Phase 1 / Phase 2 | terminated | Jul 11, 2017 | GT Biopharma, Inc. | Development of GTB-3550 halted due to development of the second generation camelid nanobody TriKE… | Other (stated, no rule matched) |
| NCT05246384 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in… | Phase 1 / Phase 2 | withdrawn | Feb 18, 2022 | Rhizen Pharmaceuticals SA | Change in development plan | Other (stated, no rule matched) |
| NCT02448095 | Retrospective Evaluation of CML Patients in the National Compassionate Program | — | terminated | May 19, 2015 | Gruppo Italiano Malattie EMatologiche dell'Adulto | lack of interest | Other (stated, no rule matched) |
| NCT03410407 | Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)(AML1617) | — | terminated | Jan 25, 2018 | Gruppo Italiano Malattie EMatologiche dell'Adulto | lack of interest | Other (stated, no rule matched) |
| NCT01570465 | Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients(AML1411) | — | terminated | Apr 4, 2012 | Gruppo Italiano Malattie EMatologiche dell'Adulto | low interest | Other (stated, no rule matched) |
| NCT04496999 | HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.(HDMM) | Phase 1 | terminated | Aug 4, 2020 | Insel Gruppe AG, University Hospital Bern | Insufficient recruitment | Enrollment / accrual |
| NCT03516760 | Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia | Phase 1 | terminated | May 4, 2018 | AvenCell Europe GmbH | The actions and measures to be taken to restart the trial could not be implemented which made the… | Other (stated, no rule matched) |
| NCT04282174 | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies(2019-KOE-001) | Phase 2 | withdrawn | Feb 24, 2020 | Baptist Health South Florida | Study was split into two new studies before the first participant was enrolled. | Enrollment / accrual |
| NCT03218683 | Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory… | Phase 1 | terminated | Jul 14, 2017 | AstraZeneca | Sponsor Decision | Sponsor / business decision |
| NCT04425655 | Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed… | Phase 2 | terminated | Jun 11, 2020 | University of California, San Diego | Original investigator for the trial has left | Investigator |
| NCT04272203 | A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose… | Phase 1 | terminated | Feb 17, 2020 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02267863 | A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS | Phase 1 | terminated | Oct 20, 2014 | Aptose Biosciences Inc. | Drug manufacturing process and procedure review | Drug supply |
| NCT04406207 | Endogenous Retroviruses in Acute Myeloid Leukemia(ERVAL) | — | withdrawn | May 28, 2020 | Hospices Civils de Lyon | COVID-19 | COVID-19 / pandemic |
| NCT04006496 | AML Expressive Writing | N/A | terminated | Jul 5, 2019 | Duke University | Recruitment issues due to COVID-19 pandemic. | COVID-19 / pandemic |
| NCT03760666 | A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | terminated | Nov 30, 2018 | Clear Creek Bio, Inc. | No efficacy observed, COVID-19 caused sites to shut down | COVID-19 / pandemic |
| NCT02773732 | Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute… | Phase 1 / Phase 2 | terminated | May 16, 2016 | University of Florida | slow enrollment | Enrollment / accrual |
| NCT01550185 | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | terminated | Mar 9, 2012 | Roswell Park Cancer Institute | Sponsor wanted study rewritten | Other (stated, no rule matched) |
| NCT05001451 | Study of GDX012 in Patients With MRD Positive AML | Phase 1 | terminated | Aug 12, 2021 | GammaDelta Therapeutics Limited | This was a business decision to discontinue this clinical trial. The decision is not related to the… | Safety / toxicity |
| NCT01773395 | GVAX vs. Placebo for MDS/AML After Allo HSCT | Phase 2 | terminated | Jan 23, 2013 | Dana-Farber Cancer Institute | Recommendation by the Data and Safety Monitoring Board due to efficacy concerns | Safety / toxicity |
| NCT01640301 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid… | Phase 1 / Phase 2 | terminated | Jul 13, 2012 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT00961142 | Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity…(CD3/CD19 Haplo) | Phase 2 | terminated | Aug 18, 2009 | University Hospital Tuebingen | slow recruitment | Enrollment / accrual |
| NCT04006847 | Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid… | Phase 1 / Phase 2 | terminated | Jul 5, 2019 | Milton S. Hershey Medical Center | Product complaint | Other (stated, no rule matched) |
| NCT04093505 | Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients…(GnG) | Phase 3 | terminated | Sep 18, 2019 | University Hospital Heidelberg | Study turned out no longer feasible. End of Recruitment: 25.5.2022 | Enrollment / accrual |
| NCT01177540 | Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in… | Phase 2 | terminated | Aug 9, 2010 | Eisai Inc. | The study was terminated early due to enrollment difficulties and the futility of observing… | Efficacy / futility |
| NCT03850535 | A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine… | Phase 1 / Phase 2 | terminated | Feb 21, 2019 | Hoffmann-La Roche | Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2. | Sponsor / business decision |
| NCT04326439 | AflacLL1901 (CHOA-AML) | Phase 2 | terminated | Mar 30, 2020 | Emory University | Due to unforeseen circumstances, the study team was limited in enrolling patients on this trial;… | Enrollment / accrual |
| NCT05279859 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic…(HERKULES-4) | Phase 1 / Phase 2 | withdrawn | Mar 15, 2022 | Erasca, Inc. | Sponsor decision. | Sponsor / business decision |
| NCT04655391 | Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute… | Phase 1 | withdrawn | Dec 7, 2020 | City of Hope Medical Center | Drug availability | Drug supply |
| NCT03063203 | Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia | Phase 2 | terminated | Feb 24, 2017 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT04676243 | Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in…(Q-SOC) | Phase 3 | withdrawn | Dec 19, 2020 | University Hospital Heidelberg | Study turned out no longer feasible | Other (stated, no rule matched) |
| NCT02999854 | Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation…(HATCY) | Phase 3 | terminated | Dec 21, 2016 | Kiadis Pharma | Insufficient efficacy, terminated by Sponsor | Efficacy / futility |
| NCT03552029 | Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia… | Phase 1 | terminated | Jun 11, 2018 | Daiichi Sankyo | This study was terminated based on a business decision by the Sponsor. | Sponsor / business decision |
| NCT00968864 | T-cell Depleted Alternative Donor Transplantation | Phase 2 | terminated | Aug 31, 2009 | Wake Forest University Health Sciences | Sponsor/ PI leaving institution, no plans to continue this research at this time | Other (stated, no rule matched) |
| NCT02927938 | Leukemia Stem Cell Detection in Acute Myeloid Leukemia | Phase 3 | terminated | Oct 7, 2016 | Wake Forest University Health Sciences | Study terminated 7/23/2019 due to limited participation and testing challenges. | Other (stated, no rule matched) |
| NCT03600909 | A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients… | Phase 2 | terminated | Jul 26, 2018 | Memorial Sloan Kettering Cancer Center | Accrual has been slow | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 2, 2023source: clinicaltrials